with lethal organ dysfunction in the renal, pulmonary and cardiac systems.
Materials and methods
A major cause of morbidity and mortality following bone marrow transplantation is toxicity induced by intensive conPatients and conditioning regimen ditioning regimens. The incidence of severe organ dysfunction has increased with the use of more intensive conditioning therapy and stem cell grafts with greater human AT-III-treated patient group: From April 1995 to May leukocyte antigen (HLA) disparity between donor and 1996, 10 patients were treated with AT-III concentrate for recipient. Hepatic toxicity (veno-occlusive disease, VOD) severe organ dysfunction following BMT. has been the focus of many studies because of its high frePatients were conditioned with a non-radiation containquency of occurrence (20-50%) and associated mortality ing regimen that included busulfan (16 doses orally every (30-50%). [1] [2] [3] [4] Furthermore, hepatic VOD is often associated 6 h, days −9 to −6), cyclophosphamide (50 mg/kg/day i.v., days −5 to −2), and etoposide (300 mg/mg 2 /day as a continuous i.v. infusion, days −5 to −3). Busulfan was dosed at 40 mg/m 2 /dose (total dose of 640 mg/m 2 ) in one patient, performed following the first and fifth doses. Their busulfan an autologous BMT was 12-20 h. 24 Based on these kinetic studies, our patients were treated with a loading dose of dose was between 0.7 to 0.9 mg/kg/dose (total doses 11.2-14.4 mg/kg). Anti-thymocyte globulin (ATG) was given to AT-III concentrate of 50 units/kg body weight every 8 h for three doses. Daily doses of AT-III were started 24 h patients receiving unrelated bone marrow or cord blood (40 mg/kg/day, BMT days −3, −2 and −1). Graft-versusafter the last loading dose at 50 units/kg body weight. Daily doses were continued depending upon response (decreases host disease (GVHD) prophylaxis for patients receiving unrelated bone marrows and cord bloods consisted of ATG in either hepatic tenderness on physical examination, organ dysfunction or platelet requirement) for 3-6 days in nine (20 mg/kg/day, BMT days +2, +4 and +6), methylprednisolone (1 mg/kg/day, days −4 to +19, tapered days +20 to patients and for 11 days in one patient. All doses were rounded to the nearest 500 units since this is the dosage +33), and cyclosporin A (days −2 to 9 months post-BMT, level maintained 275-375 ng/ml by TDX analysis on parent per vial. compound (Abbott Laboratories, Abbott Park, IL, USA) ( Table 1) .
Measurement of AT-III anticoagulant level
AT-III was measured by a functional assay using the Historical control patient group: From August 1992 to ThromboScreen antithrombin III assay kit (Pacific HemostApril 1995, 40 consecutive patients received a BMT using asis, Huntersville, NC, USA). Clotting times were perforconditioning therapy similar to the AT-III-treated patient med on the BBL Fibrometer (Becton Dickinson, Cockeysgroup. Eleven of the 40 patients were diagnosed with VOD ville, MD, USA). and/or organ dysfunction of the renal, pulmonary, or cardiac systems.
Conditioning therapy for the controls was identical to Definition of VOD that of the 10 AT-III-treated patients with the exception A clinical diagnosis of hepatic VOD was defined as jaunthat the dose of etoposide was 500 mg/m 2 /day for seven of dice (bilirubin Ͼ 1.5 mg/dl), weight gain (more than 5% the 11 control patients instead of 300 mg/m 2 /day (Table 1) . above the pre-BMT baseline weight), and right upper quadrant tenderness or massive ascites compromising Treatment schedule respiratory status. Autopsy evaluations were obtained in six control patients and in two patients treated with AT-III.
Patients with an AT-III anticoagulant level of greater than
The presence of hepatic VOD (by clinical definition) was 88% of control (normal range 88-126%) and who showed confirmed at autopsy in six patients. evidence of VOD or other life-threatening organ dysfunction received AT-III concentrate (Bayer Pharmaceutical).
Toxicity scoring system The goal of the AT-III replacement was to achieve an AT-III level greater than 120%. The AT-III levels were
Patients were graded for toxicity using a modified scoring obtained but not evaluated at the initiation of treatment so system first developed by Bearman (Table 2) . 25 The score we assumed an AT-III level of 40-50% in patients showing for each organ was defined as the highest score achieved signs of organ dysfunction. Each unit/kg of AT-IIII concenbetween 2 days prior to BMT (completion of chemotrate given has been shown to result in a 1.4% activity therapy) and 30 days after BMT (100 days for pulmonary increase. 23 The half-life of AT-III in patients who received toxicity). Four organ systems (hepatic, renal, pulmonary and cardiac) were scored. Life threatening toxicity was defined as grade 3. Hepatic and cardiac toxicity scores were Congestive heart failure with poor response to pressor support, unrelated to infection
(1) BMT patients treated with AT-III for hepatic VOD of the AT-III-treated group and control group are outlined in Tables 3 and 4 . compared to all BMT patients who developed VOD and were not treated with AT-III.
AT-III levels on the day prior to treatment were low in all patients treated with AT-III (less than 88% of control, (2) BMT patients treated with AT-III for grade 3 (lifethreatening) organ dysfunction in the hepatic, renal, mean 63%, range 40-74%). Anticoagulant activity was measured within 24 h of receiving the loading dose of ATpulmnary, or cardiac systems (as defined above) compared to all BMT patients not treated with AT-III who III in nine patients (mean 195%, range 86-280%). AT-III levels were measured in three historical controls because developed grade 3 toxicity in these same organs.
of a coagulopathy and were low in each case (35, 59 and 65%). From August 1992 to May 1996, 50 BMT patients received the same three-drug regimen (busulfan, cyclophosphamide
To determine the effect of AT-III on mortality due to organ dysfunction in patients with VOD, the probability and etoposide). Patients in groups 1 and 2 include all the patients that received this conditioning therapy and of death due to organ dysfunction was compared between patients with VOD who received AT-III and historical developed either VOD or grade 3 toxicity in the hepatic, renal, pulmonary or cardiac organ systems. controls who did not receive AT-III. Patients with VOD who received AT-III were less likely Patients with VOD (group 1) included 10 patients treated with AT-III and eight control patients.
to die from organ dysfunction, 25 vs 62%; P = 0.047 (Figure 1 ), two-sided Fisher Exact analysis P = 0.015. Patients with grade 3 toxicity (group 2) included eight patients treated with AT-III and nine control patients.
Deaths occurring in patients whose organ dysfunction had resolved prior to death were censored at the time of death. Deaths prior to 100 days after BMT in the AT-III treated Statistical analysis group were due to a combination of graft failure, infection and organ dysfunction in two patients, graft failure and The probability of dying of organ dysfunction was calculated by Kaplan-Meier analysis and the significance infection in one patient, GVHD with infection in one patient, and GVHD in one patient. The clinical manifesbetween the AT-III-treated and control groups was tested by a two-sided Fisher Exact analysis. 26 Death was counted tations of VOD had resolved completely or substantially in three patients, and two patients had only transient improveas an event if the initial organ dysfunction for which the patient was treated with AT-III, or included as a control, ment prior to death. Five of ten patients treated with AT-III survived for longer than 100 days and had resolution of was present at the time of death. If the organ dysfunction(s) resolved or became clinically insignificant prior to death, VOD compared to two of eight control patients. Deaths among historical controls were due solely to sevthe event was censored.
ere multiorgan dysfunction in five of six patients and combined with GVHD in the sixth patient. Four of these patients presented initially with VOD but followed 30-60 Results days later with multiorgan failure, while two patients died of multiorgan failure occurring simultaneously with the Ten patients were treated with AT-III for clinically significant VOD. VOD was the only significant organ dysfunction onset of VOD. The initial sign of clinical improvement in patients with in two patients. Eight patients had VOD plus additional organ dysfunction involving renal (six) or pulmonary (six) VOD was an increased response to platelet transfusions in all nine patients who were refractory to platelet transorgan systems. Organ dysfunction to three or more organ systems occurred in four patients. The median day of onset fusions. Five patients responded within 2 days of the AT-III loading dose with the remaining responses occurring 3-of organ dysfunction for patients with VOD was day +7 (range day −3 to day +14). The characteristics and outcome 5 days after initiation of treatment. Improved response to 874 platelet transfusion was followed within 48 h by reduction The patient whose ascites failed to respond to treatment was anuric for more than 2 months due to severe renal in hepatic pain (tested by palpation of the liver) in six of eight evaluable patients. Hepatic pain could not be assessed toxicity occurring simultaneously with VOD. This patient became acutely refractory to platelets with the development in two patients who were sedated for mechanical ventilation.
of VOD. His platelet count, while on a platelet drip of 1 unit/h, remained less than 20 000/mm 3 . Within 24 h of Mobilization of ascitic fluid and improved urine output tended to occur after improvements in pain and platelet starting AT-III therapy, his platelet count increased to greater than 100 000/mm 3 . count. Of five patients with tense ascites, three showed substantial improvement and one showed complete resolution Two patients in the AT-III-treated group initially received tPA to treat their organ dysfunction. Their organ between 4 and 6 days from the start of therapy. Improved urine output and reduction in weight paralleled resolution dysfunction failed to respond to tPA. These patients were then placed on AT-III therapy with improvement in of ascites.
organ dysfunction.
patients, graft failure and infection in one patient, and GVHD with infection in two patients. The clinical manifestations of grade 3 toxicity resolved completely or substantially in three patients, and two patients showed minimal improvement prior to death. Three of eight patients treated with AT-III survived for more than 100 days compared to one of nine in the control patient group. In our study, age and dosage of etoposide were different between the historical control and AT-III treatment group. The historical control group tended to be younger, with eight of 11 patients 3 years of age or younger at the time of transplant compared to only two of 10 patients who received AT-III. Seven of 10 patients in the AT-III treatment group were 10 years of age or older at BMT compared to only one in the control group. To determine whether age was a factor in the outcomes of the two patient groups, we compared the toxicity scores for the patients less than or from BMT day +0 to day +30 of 3.96 (range 1-9) compared to 4.5 (range 1-9) for patients 10 years of age or older. Patients 3 years of age or younger at the time of BMT had To determine the effect of AT-III therapy on life-threatan incidence of VOD (28%) and grade 3 toxicity (32%) ening grade 3 toxicity, the probability of death due to organ that was lower than patients 10 years of age or older (58 dysfunction was compared between patients with grade 3 and 50%, respectively). In addition, survival at day 100 was (life-threatening) toxicity who received AT-III and historihigher for the younger patients than the older patients, 76 cal controls who did not receive AT-III.
vs 42%. Thus, any bias of the outcomes due to the older Patients with grade 3 toxicity who received AT-III were age of the AT-III-treated patient group should have resulted less likely to die from organ dysfunction, 34 vs 78%; in a poorer outcome for the AT-III treatment group. P = 0.034 (Figure 2 )., two-sided Fisher Exact analysis
Patients undergoing BMT starting in December 1994 P = 0.05. Deaths occurring in patients whose organ dysreceived a lower dosage of etoposide (300 mg/m 2 /day for function had resolved prior to death were censored at the 3 days instead of 500 mg/m 2 /day for 3 days). The decrease time of death. Deaths prior to 100 days after BMT in the in the dosage of etoposide did not appear to prevent death AT-III-treated patients were due to a combination of graft from multiorgan dysfunction in the historical control group. failure and infection, with organ dysfunction in two Three of 10 historical control patients that received the lower dose of etoposide died of multiorgan dysfunction. Furthermore, the average maximum toxicity scores, for all patients receiving BMT with busulfan, cyclophosphamide and etoposide between August 1992 and May 1996, who received the higher dosage of etoposide (n = 26) was 4.08 compared to 4.12 for patients receiving the lower dosage of etoposide (n = 24).
Discussion
Treatment with AT-III reduced the incidence of death from chemotherapy-induced organ dysfunction following BMT. Organ dysfunction following BMT often has an extremely complex clinical course. [5] [6] [7] [8] It has been recognized that VOD may briefly improve, only to worsen in association with other organ toxicities and/or GVHD. Several patients identified as historical controls experienced transient clini- cal improvement in organ function which was followed by function completely resolved in seven of 10 patients treated with AT-III compared to only two of 11 in the historical model. The reduction in leukocyte rolling was apparent when AT-III was administered before or after stimulation control patients. The two historical control patients, whose organ dysfunction resolved had only mild VOD with no of the endotheliium with thrombin. In vitro studies showed the effect of AT-III to be specific for thrombin-induced leuother evidence of organ dysfunction. Thus, treatment with AT-III was associated with a diminished risk of death from kocyte rolling. These studies provide a plausible mechanism whereby AT-III may reduce inflammatory injury to organ dysfunction in this small cohort of patients.
The progression of single organ dysfunction into multiorvascular endothelium by blocking thrombin-mediated interactions between leukocytes and endothelial cells. However, gan dysfunction in association with low AT-III levels has been described both in adult patients undergoing BMT and since AT-III is an inhibitor of a variety of other serine proteases, it is possible that AT-III has other actions that affect in an animal model of clinical sepsis. Haire et al 6 described a multiorgan dysfunction syndrome following BMT in organ dysfunction in addition to thrombin inhibition. adults. This paper demonstrated that the degree of drop in AT-III levels can predict whether single organ dysfunction will progress to multiorgan dysfunction. Patients with sinmultiple factors that contribute to fatal outcome in patients 
